EDWARDS LIFESCIENCES CORPORATION (EW) FY2025 Q1 P&L / Income Statement

EDWARDS LIFESCIENCES CORPORATION (EW) FY2025 Q1 P&L / Income Statement

Income statement for 2025-01-01 through 2025-03-31. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Net sales

1,412,700,000 US dollars

Cost of sales

301,600,000 US dollars

Gross profit

1,111,100,000 US dollars

Operating costs, net of other operating income (calculated)

716,300,000 US dollars

Operating income, net

394,800,000 US dollars

Other income (expense), net (calculated)

39,100,000 US dollars

Income from continuing operations before provision for income taxes

433,900,000 US dollars

Provision for income taxes

70,300,000 US dollars

Net income

356,400,000 US dollars

Transcatheter Aortic Valve Replacement

1,046,600,000 US dollars

Transcatheter Mitral and Tricuspid Therapies

115,200,000 US dollars

Surgical Structural Heart

250,900,000 US dollars

Selling, general, and administrative expenses

465,700,000 US dollars

Research and development expenses

254,600,000 US dollars

Certain litigation expenses

10,900,000 US dollars

Separation costs (Note 3)

4,200,000 US dollars

Other operating income

negative 19,100,000 US dollars

(Loss) income from discontinued operations, net of tax

negative 7,200,000 US dollars. Reported below-tax contribution to net income.

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit, plus the explicitly reported below-tax contributions, equals net income.
• Of which attributable to EDWARDS LIFESCIENCES CORPORATION: $358.00 M; to noncontrolling interests: −$1.60 M.